Tikun Olam was established in 2006 and acquired by Cannbit Pharmaceuticals in 2019. Tikun Olam-Cannbit is Israel’s first and leading supplier of cannabis. A groundbreaker in clinical research, it is renowned worldwide as a pioneer in the field of modern medical cannabis. Since its establishment, Tikun Olam-Cannbit has treated more than 30,000 patients in Israel from childhood through to old age with a variety of illnesses, and has the most experience worldwide in the treatment of patients and in alleviating their suffering through medical cannabis. The company has 13 years of experience in clinical research and more than 35 clinical and pre-clinical research studies which have been published in the world’s foremost scientific journals.

Tikun Olam-Cannbit operates throughout the value chain of the medical cannabis world, while maintaining an ecosystem that integrates values of sustainability, therapeutic continuity, and uniformity in the quality of its products. Patients are at the core of the company’s thinking, planning and action, and a unique envelope has been built for years around them. The Tikun Olam-Cannbit patients receive products according to the treatment continuity he or she needs, and we keep for each patient his or her precisely-tailored strain, with the same percentages of active ingredients that make the treatment the most effective, the most stable, and the best for each individual. Tikun Olam-Cannbit’s ecosystem includes a research and clinical trials system, genetic R&D for development of unique strains, Israeli agriculture – cultivation and propagation farms, a production facility, an advanced laboratory and technological R&D, a logistics center, a dispensary and direct delivery to the customer’s home, as well as a service and pharma system that includes patient training and counseling, while maintaining a personalized treatment sequence.

Company Management

Former member of the 19th Knesset which introduced the Prevention of Sexual Harassment Law and the Proper Representation of Women in Local Authorities Law. In 2019 she was appointed general manager of Cannbit, which embarked on an IPO that year and led the acquisition of Tikun Olam. Until 2019 she served in a variety of positions, including VP Business Development in the Danel Group, head of the Youth Division in the Ministry for Negev and Galilee Development, head of education and welfare in the Local Government Center, and other social and educational positions.

Ifat Kariv

CEO of Tikun Olam-Cannbit

leads our clinical research, data collection and database management, analysis, and product development, with the goal of reaching the highest level of cannabis products, while conducting innovative and groundbreaking collaborations in the field. Lihi is a doctoral student in epidemiology at the Clinical Research Center at Soroka Medical Center and Ben-Gurion University, under the supervision of Prof. Victor Novak and Prof. Raphael Mechoulam, the father of medical cannabis research.

Lihi Bar-Lev Schleider

Head of R&D and Founder of the research department

previously served as controller with the Malibu Israel Group, and as finance manager of various companies in Azrieli Group, and in other public companies. He served as a portfolio auditor at accounting firm Somekh Chaikin and as an economist with the Manufacturers Association and in the Coordination Bureau of Economic Organizations. Liad holds a bachelor’s degree in economics, business administration and accounting from Bar Ilan University and is a graduate of the Directors in Industry course of the Manufacturers Association.

Liad Anani


has proven experience in creating international partnerships and in managing technological projects in the world of healthcare. Guy, a graduate of the Naval Officers Course (Major, Res.), gained a bachelor’s degree in political science and business administration in the framework of his military service, a second bachelor’s degree in plant science and biotechnology from the Hebrew University, and a master’s degree from the Department of Molecular Genetics at the Weizmann Institute of Science.

Guy Haim

VP Business Development

Eshel has been involved in the global cannabis industry for seven years, starting out at Tikun Olam’s agricultural farm, from where he moved to California. It was there that he set up and managed projects for the industry and pioneered CO2 Extraction for botanical distillation. Long before the change in the legal structure globally and in the United States, Eshel recognized the industry’s potential and established one of the earliest large-scale CBD farms in the U.S. Eshel now leads our international business development and brings his huge knowledge into play when promoting collaborations in Europe and elsewhere in the world for medical and leisure markets.

Eshel Grinberg

International Business Development

Including with Israel’s Ministry of Health and with customers and suppliers. As the company’s Pharmacist and a member of its quality assurance team, she ensures that the company’s products are manufactured, stored, and transported in accordance with the applicable standards. She checks batch quality before their release for marketing and provides professional advice to all the company’s departments. Dr. Carmi, who is an experienced pharmacist and researcher, has a bachelor’s and a master’s degree from the School of Pharmacy at the Hebrew University of Jerusalem, and a doctorate from the Faculty of Medicine at Bar-Ilan University, majoring in pharmacology and pharmacogenomics. Shani draws on her experience across all stages of drug development to promote optimal medicalization.

Dr. Shani Carmi

Responsible for the company’s regulatory and pharmacological relations

Board of Directors

Active Chairman of the company and president of the International College of Flying. During 38 years in the Israel Air Force he served as a combat pilot, and in 1996 was appointed commander of the IAF, a position which he held for four years. Co-found of East-West Ventures Ltd., and of Sentry Technology Group (STG), which operated in the USA and in Israel. Eitan was chairman of Cronus Cyber-Technologies and a director at Diamond Fund (based in Switzerland and Singapore). He is acting chairman of Aeronautics Ltd., in the drone industry, which under his leadership offered its shares on the Tel Aviv Stock Exchange with a value of 1 billion shekels.

Gen. (Res.) Eitan Ben Eliyahu

Chairman of the Board

A partner in the activities of the Canada Israel Group and founder of the Tara Group, which is active in a number of real estate projects in Israel and abroad. He has in the past served on the boards of a number of private and public companies, including Israel Bank of Agriculture and Israel Land Development Company (Hachsharat HaYishuv) Hotels. Erez, who began his entrepreneurial career as assistant and right-hand man to industrialist Stef Wertheimer, holds a law degree from the Hebrew University of Jerusalem and an MBA from the joint program of Tel Aviv University and Northwestern University in Chicago.

Erez Navon


A physician and international expert on disaster management and leadership in crisis situations, community resilience, epidemiology, and mass casualty incidents, with extensive professional and academic experience. He is considered one of the world’s leading experts in medical preparedness for emergencies and mass disasters.

Prof. Yitzhak Ashkenazi